HOME >> MEDICINE >> NEWS
Many postmenopausal women with cardiovascular disease don't use lifesaving aspirin therapy

ORLANDO, Feb.18 Low-dose aspirin therapy has been shown to reduce the chances of a secondary heart attack or stroke in women who already have cardiovascular disease (CVD). Yet, less than half of women with CVD use this over-the-counter, relatively inexpensive therapy, researchers reported today at the Second International Conference on Women, Heart Disease and Stroke.

"We know that aspirin therapy helps women who have cardiovascular disease live longer and feel better. Our study sought to characterize the extent to which women use this easily accessible therapy, as well as the disparities that exist between different groups of women," said lead author Jeffrey S. Berger, M.D., chief resident at Beth Israel Medical Center in New York.

Berger and colleagues examined data from the Women's Health Initiative Observational Study, which tracked nearly 100,000 post-menopausal women. The researchers singled out 8,928 women in the study who had a history of cardiovascular disease, including stroke and heart attack. The women had reported if they were on aspirin and other therapies.

Studies have shown that about 95 percent of the women who have cardiovascular disease should be taking aspirin, as well as other medications, to help ward off secondary heart attacks and strokes. Less than 5 percent of women with CVD might not be eligible for aspirin therapy because of side effects, such as bleeding, Berger said.

The researchers found that 4,101 (46 percent) of the women with CVD were on low-dose aspirin therapy. Only 43 percent of women with prior stroke were on aspirin therapy. And among the 2,230 patients with documented heart attacks, only 54 percent reported using aspirin.

"Ideally, the percentage of women with a known history of cardiovascular disease who take aspirin should be above 90. To find such low numbers was quite discouraging," Berger said.

Looking at the data in more detail, the researchers found that women with existing CVD
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
18-Feb-2005


Page: 1 2

Related medicine news :

1. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
2. Abdominal fat indicates severity of metabolic syndrome in obese, postmenopausal women
3. Hormone therapy may still offer important health benefits to postmenopausal women
4. New research on reduced bone mass and risk of fracture in postmenopausal women
5. Research in monkeys suggests estrogen therapy may lower androgens in postmenopausal women
6. Untreated postmenopausal women with osteoporosis
7. Estrogenlike drugs may eventually help postmenopausal women with weight gain
8. Estrogen offers no overall benefit for disease prevention in postmenopausal women with hysterectomy
9. Study finds fewer, but more advanced, colon cancers in postmenopausal women on E&P hormone therapy
10. Estrogren plus progestin decreases colorectal cancer in postmenopausal woman
11. New study details effects of exercise on sleep quality in postmenopausal women

Post Your Comments:
(Date:5/20/2013)... May 20, 2013 Co-founder of ... be a keynote speaker at the 5th International INVEST ... The conference brings together company representatives and independent individuals ... in Internet marketing and investments. , The 2013 conference ... Business Hotel México from May 20 to 21. A ...
(Date:5/20/2013)... FL (PRWEB) May 20, 2013 The ... business and community leaders behind bars for good at ... May 22 beginning at 9 a.m. , More ... annual Executive Lock-Up to benefit individuals and families affected ... present, including city officials, local celebrities, realtors, doctors, attorneys, ...
(Date:5/20/2013)... May 20, 2013 ... Who:    Sloan Gibson, President, USO and CEO ... of Outreach Initiatives and Partners, Sesame ... , Representatives from:,              ... • U.S. House ...
(Date:5/20/2013)... York (PRWEB) May 20, 2013 National law ... P.A. and Thrash Law Firm P.A., both based in Little ... approval of the proposed $7.25 billion settlement of a price-fixing ... fees. The objection was filed Wednesday, May 15, 2013, in ... York. The related lawsuit against Visa and MasterCard (Case No. ...
(Date:5/20/2013)... York, New York (PRWEB) May 20, 2013 ... a new study has found that magnetic resonance imaging (MRI) ... failure, regardless of whether or not patients are experiencing symptoms. ... the Journal of Bone & Joint Surgery, MRI detected ... In patients suffering symptoms due to mechanical causes, the ...
Breaking Medicine News(10 mins):Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:MDA to Put Fort Lauderdale Community Leaders Behind Bars for Good 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 2Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 3Health News:USO to Celebrate Five-Year Partnership of Sesame Street/USO Experience for Military Families at Biannual Care Package Service Project on Capitol Hill 4Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 2Health News:Parker Waichman LLP Takes on the Credit Card Companies, Fights for Smaller Retailers that Form the U.S. Economy’s ‘Backbone’ 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 2Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 3Health News:Metal-on-Metal Hip Replacement Lawyers Note New Study Finding MRIs Can Be Used to Predict Metal-on-Metal Hip Implant Failure 4
(Date:5/20/2013)... 2013  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical ... unique technology to deter prescription drug abuse today ... Anthony Soscia , has been chosen as ... ,s Health-Care Heroes Awards. The awards are presented ... to honor individuals and organizations demonstrating excellence and deserving ...
(Date:5/20/2013)... , May 20, 2013 Enrollment of patients ... Phase 2b dose-finding clinical trial of product candidate ... foundational treatment for Type 2 diabetes. Elcelyx expects to ... program in June. Results of the trial,s primary endpoint ... late summer, and the read-out for long-term glucose lowering ...
(Date:5/20/2013)... , May 20, 2013  Neuralstem, Inc. (NYSE MKT: ... , MD, PhD, principal investigator, presented updated Phase I ... (NSI-566) trial in the treatment of amyotrophic lateral sclerosis ... at the neuro diabetes special medical symposium in ... talk called "Recent Therapeutic Advances in Stem Cell Therapy," ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
Cached News: